Postdoctoral Fellow-MSH-13050-221 @ Mount Sinai Health System | Jobright.ai
JOBSarrow
RecommendedLiked
0
Applied
0
External
0
Postdoctoral Fellow-MSH-13050-221 jobs in United States
Be an early applicantLess than 25 applicants
company-logo

Mount Sinai Health System · 5 hours ago

Postdoctoral Fellow-MSH-13050-221

ftfMaximize your interview chances
Health CareHospital
check
Actively Hiring

Insider Connection @Mount Sinai Health System

Discover valuable connections within the company who might provide insights and potential referrals.
Get 3x more responses when you reach out via email instead of LinkedIn.

Responsibilities

Autophagy-lysosome dysfunctions in neurons and glial cells in the pathogenesis of neurodegenerative diseases
We propose to elucidate the cell-type-specific autophagy-lysosome pathways, focusing on neurons and microglia, under both physiological (young and old) and pathological conditions (Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease). Employing a systematic approach, we will incorporate multiple genetic mutant lines of mice, human-induced neuron lines (hiN), quantitative proteomics, and molecular and cell biology techniques to identify autophagy cargo and receptors in neurons and microglia. Furthermore, we will investigate the distinct mechanisms responsible for the degradation of multiple disease-associated proteins such as tau, alpha-synuclein (aSyn), and huntingtin. The findings of our study hold the potential to uncover novel biomarkers and therapeutic targets for autophagy-lysosomes in the treatment of Alzheimer’s, Parkinson’s, and Huntington’s diseases, thereby paving the way for innovative therapeutic interventions.
Dysfunctional AKAP11-PKA signaling underlying the pathogenic mechanism and in modeling psychiatric disease condition (schizophrenia and bipolar)
Recent human genetic study has identified AKAP11 as a definitive causal gene for bipolar disorder and enhanced risk factor for schizophrenia. Our study demonstrated AKAP11 is an autophagy receptor that mediates selective degradation of PKA-RI complex through autophagy. Our goal is to dissect the pathogenic mechanism whereby AKAP11 deficiency contributes to the psychiatric illness by characterizing genetic animal models and induced human neuron (iNeuron) models. We will test the new therapeutic ideas by targeting AKAP11-PKA signaling and activity.
Flow-cytometry
ELISA
WB
ELISPOT
QPCR
CyTOF data analyses
Mouse genetics
Molecular and cellular biology approaches
Primary neuron/glia cultures
Cellular imaging (both live and fixed)
Transcriptomics (including single-cell RNA sequencing and spatial transcriptomics)
Proteomics
Bioinformatics
Animal pathology/behavioral studies

Qualification

Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.

Flow-cytometryELISAWestern Blotting (WB)QPCRMolecular biologyCellular biologyELISPOTCyTOF data analysesMouse geneticsPrimary neuron/glia culturesCellular imagingTranscriptomicsProteomicsBioinformaticsBasic neuroscienceNeurological disorder mechanism researchAnimal pathologyBehavioral studiesProfessional writingMentoring

Required

MD or PhD
Extensive training in basic neuroscience, molecular and cellular biology, animal models, and neurological disorder mechanism research.

Company

Mount Sinai Health System

company-logo
Mount Sinai Health System delivers integrated medical care, research, and medical education through its network.

Funding

Current Stage
Late Stage
Total Funding
$34.9M
Key Investors
Hearst Health Prize.Multiple Myeloma Research FoundationSteven & Alexandra Cohen Foundation
2024-06-06Grant· $0.1M
2023-11-02Grant· $7M
2023-09-20Grant· $6.2M

Leadership Team

leader-logo
Vincent Tammaro
Executive Vice President and Chief Financial Officer
linkedin
leader-logo
Beth Oliver
Senior Vice President and Chief Nursing Executive
linkedin
Company data provided by crunchbase
logo

Orion

Your AI Copilot